Information Provided By: 
Fly News Breaks for August 15, 2018
CYTX
Aug 15, 2018 | 08:17 EDT
H.C. Wainwright analyst Jason Kolbert lowered his price target on Cytori Therapeutics to $5.00 from $6.00 to account for a recent fundraising, noting that he thinks Cytori may need to raise capital again soon if the company is not able to monetize ATI-0918. However, he noted Cytori highlighted expected data from clinical trials in scleroderma and urinary incontinence and Kolbert believes good data from those trial could set the stage to file for scleroderma in Europe and UI in Japan. He keeps a Buy rating on Cytori shares.
News For CYTX From the Last 2 Days
There are no results for your query CYTX
